Editas Medicine (EDIT) Gains from Investment Securities (2015 - 2025)

Editas Medicine (EDIT) reported Gains from Investment Securities of $1.2 million for Q3 2025, up 140.76% year-over-year from $484712.2 in Q3 2024, and up 199.91% on a QoQ basis from -$1.2 million in Q2 2025.

Editas Medicine (EDIT) has 11 years of Gains from Investment Securities data on file, last reported at $1.2 million in Q3 2025.

  • Quarterly Gains from Investment Securities rose 140.76% year-over-year to $1.2 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was -$1.1 million (down 2.84% YoY) and the FY2024 annual result came in at -$3.4 million, down 222.31% from the prior year.
  • Gains from Investment Securities improved to $1.2 million in Q3 2025 per EDIT's latest filing, from -$1.2 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $6.2 million in Q2 2023 and bottomed at -$7.6 million in Q4 2021.
  • The 5-year median for Gains from Investment Securities is $341978.0 (2021), against an average of $125499.2.
  • The widest annual swing landed in 2021, when Gains from Investment Securities slumped 1026.67%; it then soared 1425.28% in 2022.
  • Tracing EDIT's Gains from Investment Securities over 5 years: stood at -$7.6 million in 2021, then jumped by 38.42% to -$4.7 million in 2022, then soared by 147.79% to $2.2 million in 2023, then tumbled by 102.67% to -$60000.0 in 2024, then surged by 2045.0% to $1.2 million in 2025.
  • Per Business Quant, the three latest EDIT Gains from Investment Securities figures stand at $1.2 million (Q3 2025), -$1.2 million (Q2 2025), and -$1.0 million (Q1 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 1,216,509.61 Bn 1,216,509.61 Bn -
2 Alterity Therapeutics 764,224.41 Bn 764,224.38 Bn -
3 Legend Biotech 2,716.00 Bn 2,715.71 Bn 242.10 Mn
4 Nanobiotix 2,248.83 Bn 2,248.77 Bn -
5 Akari Therapeutics 1,951.18 Bn 1,951.17 Bn -
6 Vertex Pharmaceuticals 113.69 Bn 106.44 Bn 2.59 Bn
7 Evaxion A 64.16 Bn 64.14 Bn -
8 Regeneron Pharmaceuticals 63.94 Bn 55.18 Bn 3.31 Bn
9 Alnylam Pharmaceuticals 40.13 Bn 37.12 Bn 959.66 Mn
10 Editas Medicine 338.62 Mn 338.62 Mn -

Historic Data

Download Data 🔒
DateValue
Sep 30, 2025 1.17 Mn
Sep 30, 2025 1.17 Mn
Jun 30, 2025 -1.17 Mn
Jun 30, 2025 -1.17 Mn
Mar 31, 2025 -1.03 Mn
Mar 31, 2025 -1.03 Mn
Dec 31, 2024 -60,000.00
Dec 31, 2024 -60,000.00
Sep 30, 2024 -2.86 Mn
Sep 30, 2024 -2.86 Mn
Jun 30, 2024 -1.24 Mn
Jun 30, 2024 -1.24 Mn
Mar 31, 2024 794,000.00
Mar 31, 2024 794,000.00
Dec 31, 2023 2.25 Mn
Dec 31, 2023 2.25 Mn
Sep 30, 2023 502,000.00
Sep 30, 2023 502,000.00
Jun 30, 2023 6.19 Mn
Jun 30, 2023 6.19 Mn
Mar 31, 2023 1.50 Mn
Mar 31, 2023 1.50 Mn
Dec 31, 2022 -4.71 Mn
Dec 31, 2022 -4.71 Mn
Sep 30, 2022 5.22 Mn
Sep 30, 2022 5.22 Mn
Jun 30, 2022 1.18 Mn
Jun 30, 2022 1.18 Mn
Mar 31, 2022 -234,000.00
Mar 31, 2022 -234,000.00
Dec 31, 2021 -7.65 Mn
Dec 31, 2021 -7.65 Mn
Sep 30, 2021 341,978.00
Sep 30, 2021 341,978.00
Jun 30, 2021 196,637.00
Jun 30, 2021 196,637.00
Mar 31, 2021 1.99 Mn
Mar 31, 2021 1.99 Mn
Dec 31, 2020 825,000.00
Dec 31, 2020 825,000.00
Sep 30, 2020 1.10 Mn
Sep 30, 2020 1.10 Mn
Jun 30, 2020 1.23 Mn
Jun 30, 2020 1.23 Mn
Mar 31, 2020 215,000.00
Mar 31, 2020 215,000.00
Dec 31, 2019 -16.53 Mn
Dec 31, 2019 -16.53 Mn
Sep 30, 2019 5.14 Mn
Sep 30, 2019 5.14 Mn
Jun 30, 2019 467,185.00
Jun 30, 2019 467,185.00
Mar 31, 2019 4.86 Mn
Mar 31, 2019 4.86 Mn
Dec 31, 2018 1.14 Mn
Dec 31, 2018 1.14 Mn
Sep 30, 2018 4.82 Mn
Sep 30, 2018 4.82 Mn
Jun 30, 2018 1.56 Mn
Jun 30, 2018 1.56 Mn
Mar 31, 2018 430,000.00
Mar 31, 2018 430,000.00
Sep 30, 2017 4.42 Mn
Sep 30, 2017 4.42 Mn
Jun 30, 2017 1.22 Mn
Jun 30, 2017 1.22 Mn
Mar 31, 2017 -69,000.00
Mar 31, 2017 -69,000.00
Dec 31, 2016 -1.98 Mn
Dec 31, 2016 -1.98 Mn
Mar 31, 2016 -2.25 Mn
Mar 31, 2016 -2.25 Mn
Dec 31, 2015 -145,000.00
Dec 31, 2015 -145,000.00
Sep 30, 2015 13,000.00
Sep 30, 2015 13,000.00